MarketLens
Sign Up

What Just Happened with Generate Biomedicines' IPO

5 months ago
SHARE THIS ON:

What Just Happened with Generate Biomedicines' IPO

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 week ago

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

Generate Biomedicines, backed by Nvidia and Amgen, went public in February. The IPO marks a key milestone for the AI-driven biotech, which counts Nvidia CEO Jensen Huang among its notable supporters.
Stock News3 weeks ago

Biotech's takeover boom may be running out of buyers

Biotech deal value hit $78B in H1 2026, nearly double 2025's full-year $42B total. RBC Capital Markets warns the pace is unlikely to hold, suggesting a slowdown ahead.
News1 months ago

Sleep apnea pill maker Apnimed files for US IPO as biotech market revives

Apnimed, a late-stage sleep apnea drug developer, filed for a US IPO on Friday, joining a revived biotech IPO market.
Stock News2 months ago

OpenAI Just Filed for an IPO. Now What?

OpenAI filed for an IPO, potentially becoming the third trillion-dollar offering this year. The filing could reshape the AI investment landscape.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

Meta Faces 29 States in Court Tuesday. The Case Could Be Big Tech's Big Tobacco Moment.

Stock News2 hours ago

Situational Awareness’ 13F Reveals an $11 Billion AI Bet That Unraveled in Under a Month

Stock News2 hours ago

Nvidia Lines Up $105 Billion For OpenAI. Here's What it Means For Investors.

Stock News3 hours ago

Tesla prepares for Cybercab launch in August starting with rides to employees, the Information reports

Stock News3 hours ago

‘Unprecedented' number of Apple users received recent spyware alert, say investigators